Diffuse intrinsic pontine gliomas (DIPGs) are highly-aggressive and difficult-to-treat brain tumors found at the base of the brain. They are glial tumors, meaning they arise from the brain’s glial tissue — tissue made up of cells that help support and protect the brain’s neurons. These tumors are found in an area of the brainstem called the pons, which controls many of the body’s most vital functions such as breathing, blood pressure, and heart rate.
Diffuse Intrinsic Pontine Glioma Epidemiology Insights
Approximately 150-300 patients are diagnosed with DIPG in the USA per year.
It almost always affects the pediatric population, with approximately 200 to 300 new annual cases in the United States
Click here to learn more about the Diffuse Intrinsic Pontine Glioma Market Landscape
The Report Covers the Diffuse Intrinsic Pontine Glioma Epidemiology Segmented by:
Diffuse Intrinsic Pontine Glioma incident cases
Diffuse Intrinsic Pontine Glioma prevalent cases
Diffuse Intrinsic Pontine Glioma treated cases
Diffuse Intrinsic Pontine Glioma diagnosed cases
Diffuse Intrinsic Pontine Glioma Market Outlook
The Diffuse Intrinsic Pontine Glioma (DIPG) market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Diffuse Intrinsic Pontine Glioma (DIPG) market trends by analyzing the impact of current Diffuse Intrinsic Pontine Glioma (DIPG) therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Diffuse Intrinsic Pontine Glioma (DIPG) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Diffuse Intrinsic Pontine Glioma (DIPG) market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Diffuse Intrinsic Pontine Glioma (DIPG) market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Companies Working in the Diffuse Intrinsic Pontine Glioma Market
Bexion Pharmaceuticals
TCRCure Biopharma Ltd.
PTC Therapeutics
And many others
Diffuse Intrinsic Pontine Glioma Therapies Covered and Analyzed in the Report:
BXQ-350
131I-Omburtamab
ONC201
Learn more about the Key Companies and Emerging Therapies in the Diffuse Intrinsic Pontine Glioma Market
Table of Contents
Key Insights
Diffuse Intrinsic Pontine Glioma Introduction
Executive Summary of Diffuse Intrinsic Pontine Glioma
Disease Background and Overview
Epidemiology and patient population
Diffuse Intrinsic Pontine Glioma Emerging Therapies
Market Access and Reimbursement of Therapies
Market Drivers
Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the report @ Diffuse Intrinsic Pontine Glioma Market Outlook
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services